Corbus Pharmaceuticals(CRBP),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

CRBP Corbus Pharmaceuticals

Closed 03-19 16:00:00 EDT

8.94

-0.11

-1.22%

盘后8.94

+0.000.00%

19:59 EDT

High9.07	Low8.56	Vol148.11K
Open8.98	D1 Closing9.05	Amplitude5.62%
Mkt Cap158.56M	Tradable Cap113.97M	Total Shares17.74M
T/O1.32M	T/O Rate1.16%	Tradable Shares12.75M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"CRBP","market":"US","secType":"STK","nameCN":"Corbus Pharmaceuticals","latestPrice":8.94,"timestamp":1773950400000,"preClose":9.05,"halted":0,"volume":148110,"hourTrading":{"tag":"盘后","latestPrice":8.94,"preClose":8.94,"latestTime":"19:59 EDT","volume":1377,"amount":12309.21,"timestamp":1773964748107,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.012154696132596817,"floatShares":12747900,"shares":17736464,"eps":-5.899999,"marketStatus":"Closed","change":-0.11,"latestTime":"03-19 16:00:00 EDT","open":8.98,"high":9.07,"low":8.5611,"amount":1318702.27263,"amplitude":0.056232,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-5.899999,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1773993600000},"marketStatusCode":5,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":9.05,"postHourTrading":{"tag":"盘后","latestPrice":8.94,"preClose":8.94,"latestTime":"19:59 EDT","volume":1377,"amount":12309.21,"timestamp":1773964748107,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.788218,"impliedVol":0.6076,"impliedVolPercentile":0.1554},"requestUrl":"/m/hq/s/CRBP","defaultTab":"news","newsList":[{"id":"2620717172","title":"Corbus Pharmaceuticals Holdings Inc. Stock Underperforms Thursday When Compared To Competitors","url":"https://stock-news.laohu8.com/highlight/detail?id=2620717172","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620717172?lang=en_us&edition=fundamental","pubTime":"2026-03-20 05:23","pubTimestamp":1773955380,"startTime":"0","endTime":"0","summary":"This article was automatically generated by MarketWatch using technology from Automated Insights.Shares of Corbus Pharmaceuticals Holdings Inc.  slipped 1.22% to $8.94 Thursday, on what proved to be an all-around poor trading session for the stock market, with the NASDAQ Composite Index  falling 0.28% to 22,090.69 and Dow Jones Industrial Average  falling 0.44% to 46,021.43.This was the stock's second consecutive day of losses.Corbus Pharmaceuticals Holdings Inc. closed 56.52% short of its 52-week high of $20.56, which the company reached on October 20th.The stock underperformed when compared to some of its competitors Thursday, as Vanda Pharmaceuticals Inc.  rose 0.12% to $8.57, Fortress Biotech Inc.  fell 0.63% to $3.14, and Viking Therapeutics Inc.  rose 1.10% to $33.92.Trading volume  remained 38,014 below its 50-day average volume of 185,406.Data source: Dow Jones Market Data, FactSet. Data compiled March 19, 2026.This content was created by MarketWatch, which is operated by Dow J","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":"8603dabb40994e59ac78c04c930c0d49","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRBP"],"gpt_icon":0},{"id":"2620262090","title":"Corbus Pharmaceuticals Holdings Inc. Stock Sheds 6.0%, Underperforms Peers","url":"https://stock-news.laohu8.com/highlight/detail?id=2620262090","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620262090?lang=en_us&edition=fundamental","pubTime":"2026-03-19 04:32","pubTimestamp":1773865920,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of Corbus Pharmaceuticals Holdings Inc. slid 6.0% to $9.05 on what proved to be an all-around poor trading session for the stock market, with the NASDAQ Composite Index falling 1.5% to 22,152.42 and Dow Jones Industrial Average falling 1.6% to 46,225.15.The stock's fall snapped a two-day winning streak.Corbus Pharmaceuticals Holdings Inc. closed 56.0% short of its 52-week high of $20.56, which the company achieved on October 20th.The stock underperformed when compared to some of its peers, as Vanda Pharmaceuticals Inc. fell 0.5% to $8.56, Fortress Biotech Inc. rose 1.3% to $3.16, and Viking Therapeutics Inc. fell 5.57% to $33.55.Trading volume totaled 192,391, compared to the 50-day average of 185,535.","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRBP"],"gpt_icon":0},{"id":"2620253520","title":"Corbus CEO Yuval Cohen to join BMO Metabolic Health Summit panel","url":"https://stock-news.laohu8.com/highlight/detail?id=2620253520","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620253520?lang=en_us&edition=fundamental","pubTime":"2026-03-18 20:05","pubTimestamp":1773835533,"startTime":"0","endTime":"0","summary":"Corbus said its CEO Yuval Cohen will participate in a moderated panel at the BMO 2026 Metabolic Health Summit in New York on March 24, 2026. The panel is scheduled for 12:45 pm ET. The release is available at .","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nNDL9yZSHH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014021.USD","IE00B64PRP62.GBP","LU2210149790.SGD","LU2095319765.USD","IE00BN0W2W23.USD","IE00B3QW5Z07.USD","LU2210150020.SGD","BK4588","CRBP","IE00BKPKM429.USD","NDAQ","IE00BGHQF748.EUR","BK4139","IE00BN0W2V16.EUR","SG9999014039.USD","BK4112","BK4585","SG9999014005.SGD","IE00BN0W2T93.GBP","SG9999014013.SGD","LU0314104364.USD"],"gpt_icon":0},{"id":"2620349258","title":"Corbus Pharmaceuticals Holdings Inc. Stock Rises Monday, Still Underperforms Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2620349258","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620349258?lang=en_us&edition=fundamental","pubTime":"2026-03-17 05:23","pubTimestamp":1773696180,"startTime":"0","endTime":"0","summary":"This article was automatically generated by MarketWatch using technology from Automated Insights.Shares of Corbus Pharmaceuticals Holdings Inc.  rallied 1.06% to $9.51 Monday, on what proved to be an all-around positive trading session for the stock market, with the NASDAQ Composite Index  rising 1.22% to 22,374.18 and the Dow Jones Industrial Average  rising 0.83% to 46,946.41.The stock's rise snapped a two-day losing streak.Corbus Pharmaceuticals Holdings Inc. closed 53.75% short of its 52-week high of $20.56, which the company reached on October 20th.The stock demonstrated a mixed performance when compared to some of its competitors Monday, as Vanda Pharmaceuticals Inc.  remained unchanged, Fortress Biotech Inc.  fell 0.32% to $3.09, and Viking Therapeutics Inc.  rose 1.07% to $36.01.Trading volume  eclipsed its 50-day average volume of 186,238.Data source: Dow Jones Market Data, FactSet. Data compiled March 16, 2026.This content was created by MarketWatch, which is operated by Dow ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRBP"],"gpt_icon":0},{"id":"2619431951","title":"Corbus Pharmaceuticals Holdings Inc. Stock Outperforms Competitors Despite Losses On The Day","url":"https://stock-news.laohu8.com/highlight/detail?id=2619431951","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619431951?lang=en_us&edition=fundamental","pubTime":"2026-03-14 05:21","pubTimestamp":1773436860,"startTime":"0","endTime":"0","summary":"This article was automatically generated by MarketWatch using technology from Automated Insights.Shares of Corbus Pharmaceuticals Holdings Inc.  slid 1.88% to $9.41 Friday, on what proved to be an all-around grim trading session for the stock market, with the NASDAQ Composite Index  falling 0.93% to 22,105.36 and Dow Jones Industrial Average  falling 0.26% to 46,558.47.This was the stock's second consecutive day of losses.Corbus Pharmaceuticals Holdings Inc. closed 54.23% short of its 52-week high of $20.56, which the company reached on October 20th.The stock demonstrated a mixed performance when compared to some of its competitors Friday, as Vanda Pharmaceuticals Inc.  fell 5.17% to $8.81, Fortress Biotech Inc.  fell 5.49% to $3.10, and Viking Therapeutics Inc.  rose 0.45% to $35.63.Trading volume  remained 43,521 below its 50-day average volume of 186,425.Data source: Dow Jones Market Data, FactSet. Data compiled March 13, 2026.This content was created by MarketWatch, which is operat","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRBP"],"gpt_icon":0},{"id":"2619215619","title":"Corbus Pharmaceuticals Holdings Inc. Stock Underperforms Thursday When Compared To Competitors","url":"https://stock-news.laohu8.com/highlight/detail?id=2619215619","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619215619?lang=en_us&edition=fundamental","pubTime":"2026-03-13 05:20","pubTimestamp":1773350400,"startTime":"0","endTime":"0","summary":"This article was automatically generated by MarketWatch using technology from Automated Insights.Shares of Corbus Pharmaceuticals Holdings Inc.  shed 8.05% to $9.59 Thursday, on what proved to be an all-around grim trading session for the stock market, with the NASDAQ Composite Index  falling 1.78% to 22,311.98 and Dow Jones Industrial Average  falling 1.56% to 46,677.85.The stock's fall snapped a three-day winning streak.Corbus Pharmaceuticals Holdings Inc. closed 53.36% below its 52-week high of $20.56, which the company achieved on October 20th.The stock underperformed when compared to some of its competitors Thursday, as Vanda Pharmaceuticals Inc.  remained unchanged, Fortress Biotech Inc.  rose 1.86% to $3.28, and Viking Therapeutics Inc.  fell 0.81% to $35.47.Trading volume  eclipsed its 50-day average volume of 186,246.Data source: Dow Jones Market Data, FactSet. Data compiled March 12, 2026.This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatc","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRBP"],"gpt_icon":0},{"id":"2618976084","title":"Corbus Pharmaceuticals files $300M mixed securities shelf","url":"https://stock-news.laohu8.com/highlight/detail?id=2618976084","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618976084?lang=en_us&edition=fundamental","pubTime":"2026-03-12 05:10","pubTimestamp":1773263415,"startTime":"0","endTime":"0","summary":"17:07 EDT Corbus Pharmaceuticals (CRBP) files $300M mixed securities shelf Published first on TheFly – the ultimate source for real-time, market-mo...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/corbus-pharmaceuticals-files-300m-mixed-securities-shelf-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/corbus-pharmaceuticals-files-300m-mixed-securities-shelf-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","CRBP"],"gpt_icon":0},{"id":"2618167976","title":"Corbus Pharmaceuticals Holdings Inc Files for Mixed Shelf of up to $300 Mln - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2618167976","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618167976?lang=en_us&edition=fundamental","pubTime":"2026-03-12 05:07","pubTimestamp":1773263245,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260311:nFWN3ZZ172:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","CRBP"],"gpt_icon":0},{"id":"2618975132","title":"Corbus Pharmaceuticals Holdings Inc. Stock Climbs 3.9%, Outperforms Peers","url":"https://stock-news.laohu8.com/highlight/detail?id=2618975132","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618975132?lang=en_us&edition=fundamental","pubTime":"2026-03-12 04:35","pubTimestamp":1773261300,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of Corbus Pharmaceuticals Holdings Inc. rose 3.9% to $10.43 on what proved to be an all-around mixed trading session for the stock market, with the NASDAQ Composite Index rising 0.1% to 22,716.13 and the Dow Jones Industrial Average falling 0.6% to 47,417.27.This was the stock's third consecutive day of gains.Corbus Pharmaceuticals Holdings Inc. closed 49.3% short of its 52-week high of $20.56, which the company achieved on October 20th.The stock outperformed some of its peers, as Vanda Pharmaceuticals Inc. fell 2.8% to $9.29, Fortress Biotech Inc. fell 4.2% to $3.22, and Viking Therapeutics Inc. rose 3.17% to $35.76.Trading volume totaled 268,791, compared to the 50-day average of 183,632.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRBP"],"gpt_icon":0},{"id":"2618396974","title":"Corbus Pharmaceuticals Holdings Inc. Stock Rises 5.1%, Outperforms Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2618396974","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618396974?lang=en_us&edition=fundamental","pubTime":"2026-03-11 04:34","pubTimestamp":1773174840,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of Corbus Pharmaceuticals Holdings Inc. advanced 5.1% to $10.04 on what proved to be an all-around mixed trading session for the stock market, with the NASDAQ Composite Index remaining mostly unchanged at 22,697.10 and the Dow Jones Industrial Average falling 0.1% to 47,706.51.This was the stock's second consecutive day of gains.Corbus Pharmaceuticals Holdings Inc. closed 51.2% short of its 52-week high of $20.56, which the company reached on October 20th.The stock demonstrated a mixed performance when compared to some of its peers, as Vanda Pharmaceuticals Inc. rose 10.1% to $9.56, Fortress Biotech Inc. fell 0.3% to $3.36, and Viking Therapeutics Inc. rose 3.12% to $34.66.Trading volume totaled 416,864, compared to the 50-day average of 176,971.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRBP"],"gpt_icon":0},{"id":"2618959444","title":"Corbus Pharmaceuticals Is Maintained at Outperform by Oppenheimer","url":"https://stock-news.laohu8.com/highlight/detail?id=2618959444","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618959444?lang=en_us&edition=fundamental","pubTime":"2026-03-10 22:24","pubTimestamp":1773152640,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CRBP/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 10, 2026 10:24 ET (14:24 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OPY","CRBP"],"gpt_icon":0},{"id":"2618495566","title":"Corbus Pharmaceuticals Holdings : Oppenheimer Raises Target Price to $57 From $53","url":"https://stock-news.laohu8.com/highlight/detail?id=2618495566","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618495566?lang=en_us&edition=fundamental","pubTime":"2026-03-10 21:24","pubTimestamp":1773149040,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260310:nAZN4SKI8Q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","CRBP"],"gpt_icon":0},{"id":"2618930331","title":"Corbus Pharmaceuticals price target raised to $57 from $53 at Oppenheimer","url":"https://stock-news.laohu8.com/highlight/detail?id=2618930331","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618930331?lang=en_us&edition=fundamental","pubTime":"2026-03-10 20:01","pubTimestamp":1773144104,"startTime":"0","endTime":"0","summary":"Oppenheimer analyst Leland Gershell raised the firm’s price target on Corbus Pharmaceuticals (CRBP) to $57 from $53 and keeps an Outperform rating ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/corbus-pharmaceuticals-price-target-raised-to-57-from-53-at-oppenheimer-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/corbus-pharmaceuticals-price-target-raised-to-57-from-53-at-oppenheimer-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CRBP","OPY"],"gpt_icon":0},{"id":"2618672534","title":"Corbus Pharmaceuticals Holdings Inc. Stock Rallies 19.2%, Outperforms Peers","url":"https://stock-news.laohu8.com/highlight/detail?id=2618672534","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618672534?lang=en_us&edition=fundamental","pubTime":"2026-03-10 04:32","pubTimestamp":1773088320,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of Corbus Pharmaceuticals Holdings Inc. climbed 19.2% to $9.55 on what proved to be an all-around positive trading session for the stock market, with the NASDAQ Composite Index rising 1.4% to 22,695.95 and the Dow Jones Industrial Average rising 0.5% to 47,740.80.The stock's rise snapped a two-day losing streak.Corbus Pharmaceuticals Holdings Inc. closed 53.6% short of its 52-week high of $20.56, which the company reached on October 20th.The stock outperformed some of its peers, as Vanda Pharmaceuticals Inc. rose 10.0% to $8.68, Fortress Biotech Inc. rose 0.9% to $3.37, and Viking Therapeutics Inc. rose 1.91% to $33.61.Trading volume totaled 512,720, compared to the 50-day average of 169,064.","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRBP"],"gpt_icon":0},{"id":"2618623671","title":"Corbus Pharmaceuticals reports Q4 EPS ($1.25), consensus ($1.58)","url":"https://stock-news.laohu8.com/highlight/detail?id=2618623671","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618623671?lang=en_us&edition=fundamental","pubTime":"2026-03-09 19:36","pubTimestamp":1773056160,"startTime":"0","endTime":"0","summary":"“Our encouraging data readouts for CRB-701 and CRB-913 in the fourth quarter of 2025 set the stage for a potentially transformative 2026. This summ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/corbus-pharmaceuticals-reports-q4-eps-1-25-consensus-1-58-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/corbus-pharmaceuticals-reports-q4-eps-1-25-consensus-1-58-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CRBP"],"gpt_icon":0},{"id":"2618287076","title":"Corbus Pharmaceuticals Q4 EPS $(1.25) Beats $(1.38) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2618287076","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618287076?lang=en_us&edition=fundamental","pubTime":"2026-03-09 19:33","pubTimestamp":1773056037,"startTime":"0","endTime":"0","summary":"Corbus Pharmaceuticals (NASDAQ:CRBP) reported quarterly losses of $(1.25) per share which beat the analyst consensus estimate of $(1.38) by 9.42 percent. This is a 60.26 percent decrease over losses of $(0.78) per share","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/03/51123324/corbus-pharmaceuticals-q4-eps-1-25-beats-1-38-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRBP"],"gpt_icon":0},{"id":"2618282796","title":"Corbus Pharmaceuticals Q4 net loss rises 116% to USD 20.56 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2618282796","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618282796?lang=en_us&edition=fundamental","pubTime":"2026-03-09 19:30","pubTimestamp":1773055833,"startTime":"0","endTime":"0","summary":"Corbus reported a Q4 net loss of USD 20.56 million, up 116% year over year, with net loss per share of USD 1.25. Operating expenses in Q4 rose 74% to USD 21.97 million, driven by higher clinical development spending. For FY 2025, the company posted a net loss of USD 78.54 million and R&D expense of USD 70.1 million. Corbus ended 2025 with USD 163.3 million in cash, cash equivalents and investments and said this is expected to fund operations into 2028 following a USD 75 million public offering. The company said it expects CRB-701 monotherapy data in mid-2026 and completion of the 12-week CANYON-1 Phase 1b obesity study of CRB-913  in summer 2026.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260309:nNDL5K3t2X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","SG9999014021.USD","IE00BKPKM429.USD","SG9999014005.SGD","IE00B3QW5Z07.USD","LU2095319765.USD","BK4588","IE00BGHQF748.EUR","LU0314104364.USD","SG9999014013.SGD","SG9999014039.USD","BK4585","LU2210149790.SGD","BK4112","CRBP","LU2210150020.SGD","NDAQ","BK4139"],"gpt_icon":0},{"id":"2618491628","title":"Corbus Pharmaceuticals Q4 Basic EPS USD -1.25","url":"https://stock-news.laohu8.com/highlight/detail?id=2618491628","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618491628?lang=en_us&edition=fundamental","pubTime":"2026-03-09 19:30","pubTimestamp":1773055801,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260309:nPLX2598EF:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CRBP","BK4139"],"gpt_icon":0},{"id":"2618623838","title":"Corbus Pharmaceuticals Reports Q4 and 2025 Financial Results and Provides a Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2618623838","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618623838?lang=en_us&edition=fundamental","pubTime":"2026-03-09 19:30","pubTimestamp":1773055800,"startTime":"0","endTime":"0","summary":"Presented data at ESMO 2025 demonstrating promising efficacy with CRB-701 in head and neck squamous cell carcinoma (HNSCC) and cervical cancerCRB-701 data for both indications is expected in mid-2026 ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/09/3251723/0/en/Corbus-Pharmaceuticals-Reports-Q4-and-2025-Financial-Results-and-Provides-a-Corporate-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4080","BK4231","CRBP","SITC"],"gpt_icon":0},{"id":"2617680329","title":"Corbus Pharmaceuticals Holdings Inc  expected to post a loss of $1.58 a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2617680329","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617680329?lang=en_us&edition=fundamental","pubTime":"2026-03-06 20:40","pubTimestamp":1772800806,"startTime":"0","endTime":"0","summary":"Corbus Pharmaceuticals Holdings Inc  expected to post a loss of $1.58 a share - Earnings Preview Corbus Pharmaceuticals Holdings Inc CRBP.OQ CRBP.O is expected to  show a rise in quarterly revenue whe","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260306:nL8N3ZU18D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRBP","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.corbuspharma.com","stockEarnings":[{"period":"1week","weight":-0.1323},{"period":"1month","weight":0.1971},{"period":"3month","weight":0.1173},{"period":"6month","weight":-0.213},{"period":"1year","weight":0.4297},{"period":"ytd","weight":0.1118}],"compareEarnings":[{"period":"1week","weight":-0.022},{"period":"1month","weight":-0.0298},{"period":"3month","weight":-0.0222},{"period":"6month","weight":-0.0034},{"period":"1year","weight":0.179},{"period":"ytd","weight":-0.03}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.636364,"avgChangeRate":0.363358},{"month":2,"riseRate":0.363636,"avgChangeRate":-0.048678},{"month":3,"riseRate":0.636364,"avgChangeRate":0.194386},{"month":4,"riseRate":0.5,"avgChangeRate":0.045906},{"month":5,"riseRate":0.636364,"avgChangeRate":0.079186},{"month":6,"riseRate":0.272727,"avgChangeRate":-0.065346},{"month":7,"riseRate":0.272727,"avgChangeRate":-0.050382},{"month":8,"riseRate":0.636364,"avgChangeRate":0.095672},{"month":9,"riseRate":0.272727,"avgChangeRate":-0.086452},{"month":10,"riseRate":0.181818,"avgChangeRate":-0.124298},{"month":11,"riseRate":0.727273,"avgChangeRate":0.130055},{"month":12,"riseRate":0.272727,"avgChangeRate":-0.132264}],"exchange":"NASDAQ","name":"Corbus Pharmaceuticals","nameEN":"Corbus Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Corbus Pharmaceuticals(CRBP),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Corbus Pharmaceuticals(CRBP) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Corbus Pharmaceuticals,CRBP,Corbus Pharmaceuticals股票,Corbus Pharmaceuticals股票老虎,Corbus Pharmaceuticals股票老虎国际,Corbus Pharmaceuticals行情,Corbus Pharmaceuticals股票行情,Corbus Pharmaceuticals股价,Corbus Pharmaceuticals股市,Corbus Pharmaceuticals股票价格,Corbus Pharmaceuticals股票交易,Corbus Pharmaceuticals股票购买,Corbus Pharmaceuticals股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Corbus Pharmaceuticals(CRBP),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Corbus Pharmaceuticals(CRBP) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction